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the incidence of herpes zoster per 1,000 person-years over 3 years, broken down by age group (60 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, and 90+) ; the burden-of-illness scores for cases of herpes zoster; the probability of persistent PHN at 182 days after onset; the duration of persistent PHN from the start of the episode; the risk of zoster-related death per 10,000 persons (reported by age group); and the probability of a vaccine injection site reaction.
Study designs and other criteria for inclusion in the review
The authors looked for studies of original data that provided descriptive statistics relevant to the following questions.
What is the duration of PHN?
What is the duration of vaccine efficacy?
What is the lost work productivity due to an episode of acute zoster?
The authors gave a complete report of their search, including the search terms used, and discussed the papers identified in an appendix to their paper. 
Sources searched to identify primary studies

Criteria used to ensure the validity of primary studies
The majority of the data for the study were taken from the Shingles Prevention Study, "one of the largest (40,000 subjects) randomised, controlled trials conducted in the past decade". The authors used supplementary data when this trial was unable to provide relevant data. For instance, since the follow-up in this study was limited to 3.1 years, other data sources were used to inform the assumption made about the duration of vaccine efficacy.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Nine primary studies were included, although many more papers were reviewed for inclusion. For instance, 56 studies were found on the duration of PHN, 26 studies on the duration of vaccine efficacy, and 101 studies on lost work productivity.
Methods of combining primary studies
Results of the review
Point estimates and ranges for the incidence of herpes zoster per 1,000 person-years when vaccinated were reported in full for all age groups.
Point estimates and ranges for the incidences of herpes zoster per 1,000 person-years when not vaccinated were reported in full for all age groups.
The burden-of-illness scores for cases of herpes zoster were 147.1 (126.0 to 168.2) for vaccinated individuals and 177.7 (157.9 to 197.4) for non-vaccinated individuals.
The probability of persistent PHN at 182 days after onset was 2.9 (1.3 to 5.4) for vaccinated individuals and 5.1 (3.6 to 7.1) for non-vaccinated individuals.
The duration of persistent PHN from the start of the episode was 8 months (0 to 18) for vaccinated individuals and 8 months (0 to 18) for non-vaccinated individuals.
The risk of zoster-related death per 10,000 persons was: 0 (0 to 0) for age 60 to 64 years; 0.25 (0 to 0.5) for age 65 to 69 years; 0.75 (0.5 to 1.0) for age 70 to 74 years; 2.5 (0 to 4) for age 75 to 79 years; 9.5 (0 to 15) for age 80 to 84 years; and 28 (0 to 38) for ages 90+ years.
These risks were the same whether or not an individual was vaccinated.
The probability of a vaccine injection site reaction was 31.7% (28.3 to 32.6) for vaccinated individuals.
Methods used to derive estimates of effectiveness
The authors made some assumptions that were supported, where possible, by the best available evidence in terms of published literature and expert opinion.
Estimates of effectiveness and key assumptions
The duration of vaccine injection side reactions was assumed to be 2 days (0 to 5).
The duration of vaccine efficacy was assumed to be 30 years (3 to 30).
Measure of benefits used in the economic analysis
The summary measure of health benefit was the quality-adjusted life-years (QALYs). The utilities were taken from a published paper (Coplan et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic details) that referred to the Shingles Prevention Study. This source estimated utilities using the EuroQol visual analogue scale scores. The utility was 0.860 for no herpes zoster and 0.594 for patients with PHN. QALYs were estimated by multiplying the utilities by the mean discounted duration spent in each health state. The benefits were discounted at a rate of 3%. published sources. The analysis focused on physician visits, antivirals for the treatment of herpes zoster, and hospitalisation-related costs. Average wholesale prices and retail prices from online retailers were used to estimate the unit costs of antivirals. Reimbursement for hospitalisation was taken from the Medicare Provider Analysis and Review. The quantities were determined through the Markov model and the length of time spent in each health state. The cost of the vaccine was based on a published study and was varied to represent different possible prices. The costs were discounted at a rate of 3%. The price year was 2006. The unit costs were reported separately from the quantities.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
In accordance with the societal perspective, the authors measured indirect costs in relation to the effects on economic productivity. The costs of lost labour participation were informed by the US Department of Labour Bureau of Statistics. The estimate took the rate of labour participation from older persons into consideration.
Currency
US dollars ($).
Sensitivity analysis
Extensive one-way sensitivity analyses were carried out. The authors varied each input in the model using ranges informed by their review of the literature. A probabilistic sensitivity analysis was used to estimate the probability that the cost-effectiveness ratio was less than $50,000 and $100,000. This was achieved through assigning variables a distribution based on values in the literature and expert opinion.
Estimated benefits used in the economic analysis
At the base-case of 69 years of age, the number of QALYs was 9.9111 without the vaccine and 9.9095 with the vaccine (difference of 0.0016 or 0.6 days) over the lifetime of the patient.
Cost results
At the base-case of 69 years of age, the direct medical care costs of a zoster episode were $61 with the vaccine and $98 without the vaccine (difference -$37).
At the base-case of 69 years of age, the costs of lost work productivity were $29 with the vaccine and $49 without the vaccine (difference -$20).
Although the authors showed that about $1.3 billion might be saved at a vaccine cost of $50, through the reduction of herpes zoster cases, they found few circumstances in which widespread vaccination would lead to cost-savings.
Synthesis of costs and benefits
Vaccination was shown to be more cost-effective with a longer duration of efficacy. The cost-effectiveness ratio was shown to remain less than $100,000 per QALY gained for every scenario in which the vaccine cost was less than $100, regardless of the duration of efficacy.
